Darzalex 400 mg

DARZALEX 400 MG is a solution for intravenous use, containing the active ingredient daratumumab. This medication is commonly used in the management of certain hematologic conditions. It is manufactured by Janssen Inc. and originates from Canada.

DARZALEX 400 MG is primarily used in the treatment of specific types of blood cancers. It works by targeting certain proteins on the surface of cancer cells, which can help the immune system recognize and destroy these cells. This medication is often prescribed for conditions where other treatments have not been effective.

Common effects of DARZALEX 400 MG may include infusion-related reactions, such as fever, chills, and shortness of breath. Some individuals may also experience fatigue, nausea, or an increased risk of infections. These effects can vary from person to person and may not affect everyone who uses this medication.

DARZALEX 400 MG should be administered under the supervision of a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions you have before starting this treatment. Regular monitoring may be required to manage potential side effects and ensure the medication is working as intended.

DARZALEX 400 MG may interact with certain medications, including those that suppress the immune system. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and other substances that affect the immune system should also be used with caution.